序号

年度

获奖项目名称

奖励名称

等级

排名

证书编号

1

2015-12

小分子靶向抗癌药盐酸埃克替尼开发研究、产业化和推广应用

国家科学技术进步奖一等奖

国家级

5

2015-J-235-1-01-R05

2

2012-12

小分子靶向抗癌药盐酸埃克替尼开发研究、产业化和推广应用

浙江省科学技术奖一等奖

省部级

5

1201012-1

3

2017-09

小分子靶向抗癌药盐酸埃克替尼开发研究、产业化和推广应用

杰出呼吸学术贡献奖

中华医学会

1

2017-HX-J-001

4

2016

新药表皮生长因子络氨酸激酶抑制剂盐酸埃克替尼治疗晚期NSCLC精准医疗成果奖

医疗成果奖二等奖

院级

1

5

2019

最具影响力药物临床研究领军人物奖

2019年“独墅湖杯”医药创新“最具影响力药物临床研究领军人物奖”

中国药促会

1

1

2015

Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer

Ni J, Liu DY, Hu B, Li C, Jiang J, Wang HP, Zhang L.

CANCER

是

4.889

2

2012

Detection of EGFR Somatic Mutations in Non-Small Cell Lung Cancer(NSCLC) Using a Novel Mutant-Enriched Liquichip(MEL) Technology

Li, Zhang,Huiyi, Yang,Yanwei, Zhao,Wenchao, Liu,Shiyang, Wu,Jiaying, He,Xiaodi, Luo,Zeyao, Zhu,Jiasen, Xu,Qinghua, Zhou,Lifen, Ren-Heidenreich.

Current Drug Metabolism

是

5.11

第一作者

3

2013

Icotinib versus gefi tinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Yuankai, Shi,Li, Zhang,Xiaoqing, Liu,Caicun, Zhou,Li,Zhang,Shucai,Zhang,Dong,Wang,Qiang,Li,Shukui,Qin,Chunhong, Hu,Yiping,Zhang,Jianhua, Chen,Ying,Cheng,Jifeng, Feng,Helong, Zhang,Yong, Song,Yi-Long, Wu,Nong, Xu,Jianying, Zhou,Rongcheng, Luo,Chunxue, Bai,Yening, Jin,Wenchao, Liu,Zhaohui, Wei,Fenlai, Tan,Yinxiang, Wang,Lieming, Ding,Hong, Dai,Shunchang, Jiao,Jie, Wang,Li, Liang,Weimin, Zhang,Yan,

Lancet oncol

是

25.2

第五作者

4

2018

Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant

Song P, Zhang J, Shang C, Zhang L.

THORAC CANCER

是

2.656

5

2018

Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation

Hanping Wang， Li Zhang, Pei Hu，Xin Zheng，Xiaoyan Si，Xiaotong Zhang，Mengzhao Wang 

LUNG CANCER

是

4.486

6

2018

Quality of life results from a randomized, double-blinded,placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non small cell lung cancer

Si X, Zhang L, Wang H, Zhang X, Wang M, Han B, Li K, Wang Q, Shi J, Wang Z, Cheng Y, He J, Shi Y, Chen W, Wang X, Luo Y, Nan K, Jin F, Li B, Chen Y, Zhou J, Wang D

LUNG CANCER

是

4.486

7

2019

Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors

Peng Song，Jingcheng Zhang, Congcong Shang,Li Zhang

Scientific Reports

是

4.122

8

2015

Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib

Song G, Liu Y, Wang Y, Ren G, Guo S, Ren J, Zhang L, Li Z.

Clinica Chimica Acta

是

2.50

9

2013

Probing gender-specific change in IgG1 Fc-galactosylation in non-small cell lung cancer patients treated with epidermal growth factor receptor inhibitor, icotinib hydrochloride, using matrix-assisted

Chen G, Zhang L, Wang Y, Guo Y, Liu H, Li Z.

Rapid Commun. Mass Spectrom

是

2.32

10

2018

Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy

Wang H, Zhang L, Si X, Zhang X, Wang M

ONCOTARGETS THER

是

2.656